期刊文献+

突变阻断扩增法检测中国人CYP2D6*10、*14等位基因 被引量:2

Determination of CYP2D6*10 and *14 genotypes by amplification refractory mutation methods in Chinese subjects
原文传递
导出
摘要 目的根据突变阻断扩增原理,建立用于检测中国人CYP2D6*10及*14等位基因的方法。方法采用单管四引物法检测CYP2D6*10等位基因,建立等位基因特异扩增法检测CYP2D6*14等位基因,检测295名健康中国汉族人CYP2D6*10等位基因。结果CYP2D6*10及*14等位基因基因频率分别为55.8%和1.8%,295位受试者中包括1位*14/*14、6位*1/*14、3位*10/*14,基因型分布符合Hardy-Weinberg平衡(χ2=2.15,df=5,P>0.82)。结论本室建立的CYP2D6*10、*14等位基因分析法具有方便快捷、结果准确可靠的特点。 AIM To establish methods on the basis of amplification refractory mutation polymerase chain reaction (PCR) for the genotyping of CYP2D6 * 10 and * 14 allele in Chinese subjects. METHODS A single tube tetra-primers amplification method was used for the genotyping of CYP2D6 *10 allele. An allele specific amplification method was established for the genotyping of CYP2D6 *14 allele. CYP2D6 genotypes of 295 healthy Chinese subjects were analyzed. RESULTS The gene frequency of CYP2D6 * 10 and * 14 was 55.8 % and 1.8 % respectively. There were 1 * 14/ *14, 6 * 1/* 14 and 3 * 10/* 14 in 295 Chinese subjects. The CYP2D6 genotype distribution for CYP2D6*10 and 14 alleles was consistent with Hardy-Weinberg equilibrium (Χ^2 = 2.15, df = 5, P 〉 0.82). CONCLUSION The genotyping method established in our laboratory is proved to be rapid and convenient, and the results are reliable.
出处 《中国临床药学杂志》 CAS 2009年第1期1-4,共4页 Chinese Journal of Clinical Pharmacy
基金 国家自然科学基金(30271526) 优秀博士论文基金(No200368)
关键词 四引物扩增法 等位基因特异扩增法 CYP2D6*10 CYP2D6*14 基因分型 tetra-primers amplification allele specific amplification CYP2D6 * 10 CYP2D6* 14 genotyping
  • 相关文献

参考文献3

二级参考文献7

共引文献37

同被引文献13

  • 1陈瑞琳,蔺淑梅,叶峰,张曦,赵英仁,张树林.Methylation status of the interferon-gamma gene promoter in chronic hepatitis B[J].Journal of Pharmaceutical Analysis,2008,20(3):206-212. 被引量:3
  • 2李振甲,应希堂,马世俊.化学发光免疫分析技术的研究现状与展望[J].国际检验医学杂志,2006,27(1):95-96. 被引量:33
  • 3Podder H,Stepkowski SM,Napoli K,et al.Pharmacokinetic interactions between sirolimus and cyclosporine exacerbate renal dysfunction[J].Transplant Proc,2001,33(1-2):1086.
  • 4Jiao Z,Shi XJ,Li ZD,et al.Population pharmacokinetics of sirolimus in de nove Chinese adult renal transplant patients[J].Br J Clin Pharmacol,2009,68(1):47-60.
  • 5Dansirikul C,Morris RG,Tett SE,et al.A Bayesian approach for population pharmacokinetic modeling of sirolimus[J].Br J Clin Pharmacol,2006,62(4):420-434.
  • 6MacDonald A,Scarola J,Burke JT,et al.Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus[J].Clin Ther,2000,22(Suppl B):B101-B121.
  • 7Djebli N,Rousseau A,Hoizey G,et al.Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients[J].Clin Pharmacokinet,2006,45(11):1135-1148.
  • 8Miao LY,Huang CR,Hou JQ,et al.Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients[J].Biopharm Drug Dispos,2008,29(1):1-5.
  • 9Hu YF,He J,Chen GL,et al.CYP3AS*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population[J].Clini Chim Acta,2005,353(1-2):187-192.
  • 10Newton CR,Graham A,Heptinstall LE,et al.Analysis of any point mutation in DNA.The amplification refractory mutation system(ARMS)[J].Nucleic Acids Research,1989,17(7):2503-2516.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部